Colchicine for Secondary Prevention After Stroke According to the Presence of Atherosclerosis.
John J McCabe, Robin Lemmens, Francisco Purroy et al.
✦ AI-curated · Sources linked
In 30 seconds
This randomized controlled trial analyzed the effects of colchicine for secondary prevention of major adverse cardiovascular events (MACEs) after stroke, focusing on patients with and without atherosclerosis. Among 3,144 participants, those with atherosclerosis showed a non-significant reduction in MACEs with colchicine (11.1% vs 14.2% for usual care), with a hazard ratio of 0.83. The study suggests a potential benefit of colchicine in patients with atherosclerosis.
Key findings
- In the atherosclerosis group, colchicine resulted in 11.1% MACEs compared to 14.2% with usual care.
- The hazard ratio for MACEs in the atherosclerosis group was 0.83 (95% CI, 0.64-1.07).
- In on-treatment analysis, colchicine reduced MACE risk in atherosclerosis patients with a hazard ratio of 0.76 (95% CI, 0.58-0.99).
- No significant difference in MACEs was observed in the nonatherosclerosis subgroup (HR, 0.94; 95% CI, 0.64-1.39).
Why it matters
Understanding the role of anti-inflammatory therapies like colchicine in secondary prevention after stroke is crucial, particularly for patients with atherosclerosis, as it may influence future treatment strategies and clinical trial designs.